We recently evaluated treated and untreated CRC patients for celecoxib, an inhibitor of COX2, and found that cytoplasmic IDO1 and COX2, but not nuclear IDO1 and COX2, were correlated with OS in patients treated with or without celecoxib. This evidence concerns the gene PTGS2 and colorectal carcinoma.